Q-omics provides the consensus-scored MIR7155 profile across patient tissues and cancer cell-line models. MIR7155 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MIR7155 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, MIR7155 RNA expression shows 4,555 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight SKCM, and KIRC as cancer lineages where MIR7155 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR7155 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR7155 survival associations across molecular data types. MIR7155 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR7155 RNA expression–survival associations across cancer types. High MIR7155 expression shows unfavorable associations in SKCM, THCA, READ, SARC and UVM, but favorable associations in HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MIR7155 RNA expression.
This table summarizes MIR7155 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR7155. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR7155 shows higher tumor expression in KIRC. The KIRC box plot shows higher MIR7155 RNA expression in tumor versus normal tissue (log2 FC = +0.104, t-test p = .044).
This table shows molecular features associated with MIR7155 in patient tissues and cancer cell lines. In patient samples, MIR7155 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
